azathioprine of 150 [75; 150] mg per day — Competitive Intelligence Brief

azathioprine of 150 [75; 150] mg per day (azathioprine of 150 [75; 150] mg per day) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 3 Immunosuppressant Inosine monophosphate dehydrogenase Immunology Small molecule

Target snapshot

azathioprine of 150 [75; 150] mg per day (azathioprine of 150 [75; 150] mg per day) — I.M. Sechenov First Moscow State Medical University. Azathioprine is an immunosuppressive medication that works by inhibiting the synthesis of purine nucleotides, thereby suppressing the proliferation of T and B lymphocytes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
azathioprine of 150 [75; 150] mg per day TARGET	azathioprine of 150 [75; 150] mg per day	I.M. Sechenov First Moscow State Medical University	phase 3	Immunosuppressant	Inosine monophosphate dehydrogenase
XR-tacrolimus QD + MMF BID then MMF QD	XR-tacrolimus QD + MMF BID then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)
Mycophenolate Mofetil Cap./Tab.	Mycophenolate Mofetil Cap./Tab.	Chong Kun Dang Pharmaceutical	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant	IMPDH type II (inosine monophosphate dehydrogenase)
Copegus (ribavirin)	Copegus (ribavirin)	Hoffmann-La Roche	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
Mycophenolic acid dose reduction	Mycophenolic acid dose reduction	University of California, San Francisco	marketed	Immunosuppressant	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolic Acid (MPA)	Mycophenolic Acid (MPA)	Novartis	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Dexamethasone Azathioprine Pulse therapy	Dexamethasone Azathioprine Pulse therapy	Jinnah Postgraduate Medical Centre	marketed	Immunosuppressive combination therapy	Glucocorticoid receptor (dexamethasone); inosine monophosphate dehydrogenase (azathioprine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant class)

1. Assistance Publique Hopitaux De Marseille · 1 drug in this class
2. Centre Hospitalier Universitaire, Amiens · 1 drug in this class
3. Hospices Civils de Lyon · 1 drug in this class
4. I.M. Sechenov First Moscow State Medical University · 1 drug in this class
5. Kenya Medical Research Institute · 1 drug in this class
6. Memorial Sloan Kettering Cancer Center · 1 drug in this class
7. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. RWTH Aachen University · 1 drug in this class
10. Samsung Medical Center · 1 drug in this class